Overview

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory or relapsed after previous chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Chiron Corporation

Treatments:

Interleukin-2
Rituximab